Melanoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers

DelveInsight's, "Melanoma Pipeline Insight 2024" report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Melanoma research. Learn more about our innovative pipeline today! @ Melanoma Pipeline Outlook [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Melanoma Pipeline Report

* In October 2024:- Iovance Biotherapeutics, Inc.- A Phase 3, Multicenter, Randomized, Open-label, Parallel Group, Treatment Study to Assess the Efficacy and Safety of the Lifileucel (LN-144, Autologous Tumor Infiltrating Lymphocytes [TIL]) Regimen in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy in Participants With Untreated, Unresectable or Metastatic Melanoma
* In October 2024:- Regeneron Pharmaceuticals- This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and effective the combination of fianlimab and cemiplimab is in treating melanoma, in comparison with the combination of two medications, relatlimab and nivolumab, commercialized under the brand name Opdualag Trademark and approved for the treatment of melanoma in adults and children.
* In October 2024:- Amgen- A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO Registered (Nivolumab) in Subjects With Treatment-Naive Unresectable or Metastatic Melanoma. The purpose of this study is to assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naive Unresectable or Metastatic Melanoma.
* In October 2024:- Pfizer- The purpose of the study is to compare the efficacy of a triplet therapy (encorafenib, binimetinib, pembrolizumab) versus a doublet/control therapy (nivolumab and ipilimumab). Participants will have metastatic or unresectable locally advanced BRAF V600E/K-mutant melanoma, which progressed during or after prior treatment in the adjuvant or first-line metastatic setting, with an approved anti-PD-1 monotherapy (pembrolizumab or nivolumab)
* In October 2024:- Innovent Biologics (Suzhou) Co. Ltd.- A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma. This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients
* In October 2024:- Bristol-Myers Squibb- A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination Versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants With Previously Untreated Metastatic or Unresectable Melanoma. The purpose of this study is to demonstrate that the study drug exposure level of the nivolumab + relatlimab FDC subcutaneous (SC) formulation is not worse than nivolumab + relatlimab FDC intravenous (IV) administration in participants with previously untreated metastatic or unresectable melanoma.
* In October 2024: Merck Sharp & Dohme LLC- A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001). The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
* In October 2024:- Hoffmann-La Roche- A Randomized, Open-Label, Multicenter, Phase II Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma. The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK), and pharmacodynamics of two dose levels of RO7247669 in participants with unresectable or metastatic melanoma to select the recommended dose for further development.
* In October 2024:- Elizabeth Buchbinder, MD- This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied. The U.S. Food and Drug Administration (FDA) has not approved atezolizumab for this specific disease but it has been approved for other uses. The U.S. Food and Drug Administration (FDA) has not approved bevacizumab for this specific disease but it has been approved for other uses.
* In October 2024:- Istari Oncology, Inc.- This multi-center, open-label, randomized, Phase 2 will investigate the efficacy and safety of lerapolturev alone (Arm 1) or in combination with an anti-PD-1 inhibitor (Arm 2). Following a 6 participant safety run-in period, up to approximately 50 participants with cutaneous melanoma who previously failed anti-PD-1/L1-based therapy will be randomized 1:1 to receive either lerapolturev or lerapolturev plus an anti-PD-1.
* DelveInsight's Melanoma pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for Melanoma treatment.
* The leading Melanoma Companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics , and others.
* Promising Melanoma Therapies such as Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF , and others.

Stay informed about the cutting-edge advancements in Melanoma treatments. Download for updates and be a part of the revolution in cancer care @ Melanoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Melanoma Emerging Drugs Profile

* IO102 IO103 : IO Biotech

IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). IDO and/or PD-L1 are overexpressed by many types of solid tumors and immune-suppressive cells (Tregs and TAMs) in the TME. The company is developing this vaccine based on its T-win Registered vaccine platform. Currently it is in Phase III stage of clinical trial evaluation to treat Melanoma.

* mRNA 4157: Moderna Inc.

mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. The drug is been developed jointly by Moderna & Merck. Currently being evaluated in the Phase III studies.

* MK-4830: Merck Sharp & Dohme LLC

MK-4830 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with Agenus Inc. Currently the drug is being evaluated in Phase II for the treatment of Colorectal Cancer.

* BNT111: BioNTech SE

BNT111 is an intravenous therapeutic cancer immunotherapy candidate encoding a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as RNA-lipoplex formulation. The drug induces novel antigen-specific anti-tumor immune responses and enhances pre-existing immune responses against the encoded melanoma-associated antigens. The drug is in Phase II stage of clinical trials.

* TILT 123: TILT Biotherapeutics LLC

TILT-123 is a human 5/3 chimeric adenovirus that has been engineered to encode human Tumor Necrosis Factor alpha (hTNFa) and human Interleukin 2 (hIL-2) cytokines. It is optimized to generate an anti-cancer immune response by boosting the activity of T-cells and also stimulating other arms of the innate and adaptive immune system. TILT-123 can be administered by intravenous, intratumoral, intraperitoneal and intrapleural injection. The drug is in Phase I stage of clinical trials.

Learn more about Melanoma Drugs opportunities in our groundbreaking Melanoma research and development projects @ Melanoma Unmet Needs [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Melanoma Companies

IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.

Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Oral
* Parenteral
* intravenous
* Subcutaneous
* Topical.

Melanoma Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy

Discover the latest advancements in Melanoma treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Melanoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Melanoma Pipeline Report

* Coverage- Global
* Melanoma Companies- IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others.
* Melanoma Therapies- Ipilimumab, GM-CSF, Temozolomide, Tilsotolimod, Pembrolizumab, Lenvatinib, L19IL2 + L19TNF, and others.
* Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Melanoma Pipeline on our website @ Melanoma Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Melanoma: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Comparative Analysis
* IO102 IO103 : IO Biotech
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* MK-4830: Merck Sharp & Dohme LLC
* Early Stage Products (Phase I)
* Comparative Analysis
* TILT 123: TILT Biotherapeutics LLC
* Inactive Products
* Melanoma Key Companies
* Melanoma Key Products
* Melanoma- Unmet Needs
* Melanoma- Market Drivers and Barriers
* Melanoma- Future Perspectives and Conclusion
* Melanoma Analyst Views
* Melanoma Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=melanoma-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.